Validation of TURN, a simple Predictor of Symptomatic Intracerebral Hemorrhage after IV Thrombolysis
Intravenous thrombolysis (rt-PA) remains the only medical treatment for acute ischemic stroke approved by the Food and Drug Administration (FDA), but carries a substantial risk for symptomatic intracerebral hemorrhage (sICH) [1]. Predictive scores for sICH may help improve the safety profile for rt-PA treatment.
Source: Clinical Neurology and Neurosurgery - Category: Neurosurgery Authors: David Asuzu, Karin NystrÓ§m, Hardik Amin, Joseph Schindler, Charles Wira, David Greer, Nai Fang Chi, Janet Halliday, Kevin N. Sheth Source Type: research
More News: Brain | Food and Drug Administration (FDA) | Hemorrhagic Stroke | Ischemic Stroke | Neurology | Neurosurgery | Stroke